This trial demonstrates the safety of the MANTA Vascular Closure Device, which uses ultrasound to guide closure of the femoral artery, in patients undergoing elective TAVR procedures.
1 Primary · 7 Secondary · Reporting Duration: within 30 days
1 Treatment Group
1 of 1
180 Total Participants · 1 Treatment Group
Primary Treatment: MANTA Vascular Closure Device · No Placebo Group · N/A
Who is running the clinical trial?
Age 18+ · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is today's patient recruitment goal for this research project?
"The sponsor, Teleflex, needs to enroll 180 eligible patients from various clinical trial sites - including Washington Hospital Center in Washington, District of Columbia and Sentara Northern Virginia Medical Center in Woodbridge, Virginia - in order to complete the study." - Anonymous Online Contributor
If I'm interested in participating in this trial, how many different places can I go to?
"This study is being conducted in several hospitals, including Washington Hospital Center, Sentara Northern Virginia Medical Center, and University of Buffalo." - Anonymous Online Contributor
Are there any presently open vacancies for patients in this experiment?
"The trial is still recruiting patients, as indicated by the 8/24/2022 edit date on clinicaltrials.gov. The listing for this study was first posted on 8/9/2022." - Anonymous Online Contributor